In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients

Melanoma Research

Volumn 20, Issue 6, 2010, Pages 459-467

  Konjević, Gordana ^a,b   Mirjačić Martinović, Katarina ^a   Vuletić, Ana ^a   Babović, Nada ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

IFN ; IL 2; melanoma; NK cell receptors; NK cells

Indexed keywords

ALPHA INTERFERON; CD161 ANTIGEN; INTERFERON REGULATORY FACTOR 1; NATURAL KILLER CELL RECEPTOR NKG2D; RECOMBINANT INTERLEUKIN 2; RNA; STAT1 PROTEIN; STAT5 PROTEIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; MELANOMA; METASTASIS; NATURAL KILLER CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT RESPONSE; TUMOR CELL; WESTERN BLOTTING;

CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; K562 CELLS; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY B; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K;

EID: 78349306897     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32833e3286     Document Type: Article

References (41)

1. Atkins MB. Immunotherapy and experimental approaches for metastatic melanoma. Hematol Oncol Clin North Am 1998; 12:877-902.
2. Garbe C, Eigentler TK. Therapy of malignant melanoma at the stage of distant metastasis. Hautarzt 2004; 55:195-213. (Pubitemid 38391409)
3. Tarhini AA, Agarwala SS. Interleukin-2 for the treatment of melanoma. Curr Opin Investig Drugs 2005; 6:1234-1239.
4. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22:633-640.
5. Kiessling R, Klein E, Wigzell H. 'Natural' killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol1975; 5:112-117.
6. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999; 17:189-220.
7. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev 2006; 20:123-137.
8. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol2003; 3:781-790.
9. Azzoni L, Zatsepina O, Abebe B, Bennett IM, Kanakaraj P, Perussia B. Differential transcriptional regulation of CD161 and a novel gene, 197/15a, by IL-2, IL-15, and IL-12 in NK and Tcells. J Immunol1998; 161:3493-3500.
10. Aldemir H, Prod'homme V, Dumaurier MJ, Retiere C, Poupon G, Cazareth J, et al. Cutting edge: lectin-like transcript 1 is a ligand for the CD161 receptor. J Immunol 2005; 175:7791-7795.
11. Watzl C. The NKG2D receptor and its ligands-recognition beyond the 'missing self? Microbes Infect 2003; 5:31-37.
12. Naumova E, Mihaylova A, Ivanova M, Mihailova S. Impact of KIR/HLA ligand combinations on immune responses in malignant melanoma. Cancer Immunol Immunother 2007; 56:95-100.
13. Konjević G, Jović V,Vuletić A, Radulović S, Jelić S, Spuzić I. CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma. Eur J Clin Invest 2007; 37:887-896.
14. Sibbitt WL Jr, Bankhurst AD, Jumonville AJ, Saiki JH, Saiers JH, Doberneck RC. Defects in natural killer cell activity and interferon response in human lung carcinoma and malignant melanoma. Cancer Res 1984; 44:852-856.
15. Bremers AJ, Parmiani G. Immunology and immunotherapy of human cancer: present concepts and clinical developments. Crit Rev Oncol Hematol 2000; 34:1-25.
16. Lee CK, Rao DT, Gertner R, Gimeno R, Frey AB, Levy DE. Distinct requirements for IFNs and STAT1 in NK cell function. J Immunol 2000; 165:3571-3577.
17. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264:1415-1421.
18. Kröger A, Köster M, Schroeder K, Hauser H, Mueller PP. Activities of IRF-1. J Interferon Cytokine Res 2002; 22:5-14.
19. Frank DA, Robertson MJ, Bonni A, Ritz J, Greenberg ME. Interleukin 2 signaling involves the phosphorylation of Stat proteins. Proc Natl Acad Sci USA 1995; 92:7779-7783.
20. Bowmann T, Garcia R,Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000; 19:2474-2488.
21. Kovarik J, Boudny V, Kocak I, Lauerova L, Fait V, Vagundova M. Malignant melanoma associates with deficient IFN-induced STAT 1 phosphorylation. Int J Mol Med 2003; 12:335-340.
22. Lesinski GB,Valentino D, Hade EM, Jones S, Magro C, Chaudhury AR, et al. Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy. Cancer Immunol Immunother 2005; 54:815-825.
23. Varker KA, Kondadasula SV, Go MR, Lesinski GB, Ghosh-Berkebile R, Lehman A, et al. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy. Clin Cancer Res 2006; 12:5850-5858.
24. Lesinski GB, Trefry J, Brasdovich M, Kondadasula SV, Sackey K, Zimmerer JM, et al. Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells. Clin Cancer Res 2007; 13:5010-5019.
25. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol1986; 136:4480-4486.
26. Nagler A, Lanier LL, Cwirla S. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol1989; 143:3183-3191.
27. Konjević G, Martinović KM, Jurisić V, Babović N, Spuzić I. Biomarkers of suppressed natural killer (NK) cell function in metastatic melanoma: decreased NKG2D and increased CD158a receptors on CD3-CD16 + NK cells. Biomarkers 2009; 14:258-270.
28. Jackson A, Warner N. Preparation, staining and analysis by flow cytometry of peripheral blood leukocytes. In: Rose N, Friedmah H, Fahey J, editors. Manual of clinical laboratory immunology. 3rd ed. Washington DC: American Society for Microbiology; 1986. pp. 226-235.
29. Brown RL, Ortaldo JR, Griffith RL, Blanca I, Rabin H. The proliferation and function of human mononuclear leukocytes and natural killer cells in serum-free medium. J Immunol Methods 1985; 81:207-214.
30. Konjević G, Mirjacić Martinović K, Vuletić A, Jović V, Jurisić V, Babović N, Spuzić I. Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients. Clin Exp Metastasis 2007; 24:1-11.
31. Konjević G, Jurisić V, Spuzić I. Association of NK cell dysfunction with changes in LDH characteristics of peripheral blood lymphocytes (PBL) in breast cancer patients. Breast Cancer Res Treat 2001; 66:255-263.
32. Smyth MJ, Cretney E, Kelly JM, Westwood JA, Street SE, Yagita H. Activation of NK cell cytotoxicity. Mol Immunol 2005; 42:501-510.
33. Konjević G, Jović V, Jurisić V, Radulović S, Jelić S, Spuzić I. IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK-and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC. Clin Exp Metastasis 2003; 20:647-655.
34. Seidel MG, Freissmuth M, Pehamberger H, Micksche M. Stimulation of natural killer activity in peripheral blood lymphocytes of healthy donors and melanoma patients in vitro: synergism between interleukin (IL)-12 and IL-15 or IL-12 and IL-2. Naunyn Schmiedebergs Arch Pharmacol 1998; 358:382-389.
35. Fuertes MB, Girart MV, Molinero LL, Domaica CI, Rossi LE, Barrio MM, et al. Intracellular retention of the NKG2D ligand MHCclass I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J Immunol 2008; 180:4606-4614.
36. Zhang C, Zhang J, Sun R, Feng J, Wei H, Tian Z. Opposing effect of IFN gamma and IFN alpha on expression of NKG2 receptors: negative regulation of IFN gamma on NK cells. Int Immunopharmacol 2005; 5:1057-1067.
37. Epling-Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M, et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood2007; 109:4816-4824.
38. Smyth MJ, Swann J, Kelly JM, Cretney E, Yokoyama WM, Diefenbach A, et al. NKG2D recognition and perforin effectorfunction mediate effective cytokine immunotherapy of cancer. J Exp Med 2004; 10:1325-1335.
39. Kogure T, Fujinaga H, Niizawa A, Hai LX, Shimada Y, Ochiai H, et al. Killer-cell inhibitory receptors, CD158a/b, are upregulated by interleukin-2 but not interferon-gamma or interleukin-4. Mediators Inflamm 1999; 8:313-318.
40. Liang S, Wei H, Sun R, Tian Z. IFN alpha regulates NK cell cytotoxicity through STAT1 pathway. Cytokine 2003; 23:190-199.
41. Lehtonen A, Lund R, Lahesmaa R, Julkunen I, Sareneva T, Matikainen S. IFN-alpha and IL-12 activate IFN regulatory factor 1 (IRF-1), IRF-4, and IRF-8 gene expression in human NK and Tcells. Cytokine 2003; 24:81-90.